Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2–4 years: A phase II randomized study

References

• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139-46; PMID:15794968; http://dx.doi.org/10.1016/S0140-6736(05)71876-6
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495-502; PMID:17071283; http://dx.doi.org/10.1016/S0140-6736(06)69637-2
   PubMed Web of Science ®Google Scholar
• Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7; PMID:16163262
   PubMedGoogle Scholar
• Black SSH, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediat Infect Dis J 2004; 23:485-9; PMID:15194827; http://dx.doi.org/10.1097/01.inf.0000129685.04847.94
   PubMed Web of Science ®Google Scholar
• Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008; 14:835-43; PMID:18844684; http://dx.doi.org/10.1111/j.1469-0691.2008.02031.x
   PubMed Web of Science ®Google Scholar
• Cheung YB ZS, Nsekpong ED, Van Beneden CA, Adegbola RA, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediat Infect Dis J 2009; 28:990-5; PMID:19536041; http://dx.doi.org/10.1097/INF.0b013e3181a78185
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54; PMID:17922399; http://dx.doi.org/10.1086/521626
   PubMed Web of Science ®Google Scholar
• Panina EM, Mironov AA, Gelfand MS. Comparative genomics of bacterial zinc regulons: enhanced ion transport, pathogenesis, and rearrangement of ribosomal proteins. Proc Natl Acad Sci U S A 2003; 100:9912-7; PMID:12904577; http://dx.doi.org/10.1073/pnas.1733691100
   PubMed Web of Science ®Google Scholar
• Ogunniyi AD, Grabowicz M, Mahdi LK, Cook J, Gordon DL, Sadlon TA, Paton JC. Pneumococcal histidine triad proteins are regulated by the Zn2+-dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H. FASEB J 2009; 23:731-8; PMID:18971260; http://dx.doi.org/10.1096/fj.08-119537
   PubMed Web of Science ®Google Scholar
• Plumptre CD, Ogunniyi AD, Paton JC. Polyhistidine triad proteins of pathogenic streptococci. Trends Microbiol 2012; 20:485-93; PMID:22819099; http://dx.doi.org/10.1016/j.tim.2012.06.004
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8
   PubMed Web of Science ®Google Scholar
• Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001; 65:187-207; first page, table of contents; PMID:11381099; http://dx.doi.org/10.1128/MMBR.65.2.187-207.2001
   PubMed Web of Science ®Google Scholar
• Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011; 79:238-45; PMID:20956575; http://dx.doi.org/10.1128/IAI.00378-10
   PubMed Web of Science ®Google Scholar
• Denoel P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011; 29:5495-501; PMID:21624422; http://dx.doi.org/10.1016/j.vaccine.2011.05.051
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez Mdel M, Cima-Cabal MD, Florez N, Garcia P, Cernuda-Cernuda R, Astudillo A, Vazquez F, De los Toyos JR, Mendez FJ. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 2004; 72:4534-40; PMID:15271913; http://dx.doi.org/10.1128/IAI.72.8.4534-4540.2004
   PubMed Web of Science ®Google Scholar
• Adamou JE HJ, Erwin AL, Walsh W, Gayle T, et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immunol 2001; 69:949-58; PMID:11159990; http://dx.doi.org/10.1128/IAI.69.2.949-958.2001
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Maes C, De Boever F, Traskine M, Ruggeberg JU, Borys D. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Vaccine 2014; 32:6838-46; PMID:24607003; http://dx.doi.org/10.1016/j.vaccine.2014.02.052
   PubMed Web of Science ®Google Scholar
• Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapeliere PG, Verlant V, Vink PE. Randomized controlled study of pneumococcal vaccine formulations containing PhtD and dPly proteins with alum or adjuvant system AS02V in elderly adults: safety and immunogenicity. Clin Vaccine Immunol 2014; 21:651-60; PMID:24599529
   PubMed Web of Science ®Google Scholar
• Hoskins J, Alborn WE, Jr., Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 2001; 183:5709-17; PMID:11544234; http://dx.doi.org/10.1128/JB.183.19.5709-5717.2001
   PubMed Web of Science ®Google Scholar
• Prymula R,  Szenborn L, Silfverdal S, Wysocki J, Albrecht P, Francois N, Gardev A, Borys D. Safety and reactogenicity of 2 formulations of an investigational protein-based pneumococcal vaccine in infants in Europe:a phase II trial [Abstract ISPPD - 0167]. The International Symposium on Pneumococci and Pneumococcal Diseases. Hyderabad, India: Pneumonia, 2014.
   Google Scholar
• Prymula R,  Szenborn L, Silfverdal S, Wysocki J, Albrecht P, Francois N, Gardev A, Borys D. Immunogenicity of primary vaccination with an investigational protein-based pneumococcal vaccine in infants in Europe: a phase II randomization trial [Abstract - 0551]. The International Symposium on Pneumococci and Pneumococcal Diseases. Hyderabad, India: Pneumonia, 2014.
   Google Scholar
• Salha D, Szeto J, Myers L, Claus C, Sheung A, Tang M, Ljutic B, Hanwell D, Ogilvie K, Ming M, et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun 2012; 80:2212-20; PMID:22473606; http://dx.doi.org/10.1128/IAI.06348-11
   PubMed Web of Science ®Google Scholar
• Hill PC, Akisanya A, Sankareh K, Cheung YB, Saaka M, Lahai G, Greenwood BM, Adegbola RA. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis 2006; 43:673-9; PMID:16912937; http://dx.doi.org/10.1086/506941
   PubMed Web of Science ®Google Scholar
• Rapola S, Jantti V, Haikala R, Syrjanen R, Carlone GM, Sampson JS, Briles DE, Paton JC, Takala AK, Kilpi TM, et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000; 182:1146-52; PMID:10979911; http://dx.doi.org/10.1086/315822
   PubMed Web of Science ®Google Scholar
• Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001; 183:827-30; PMID:11181163; http://dx.doi.org/10.1086/318833
   PubMed Web of Science ®Google Scholar
• Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, Diallo A, Kuyinu YA, Kehinde OA, Francois N, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health 2011; 11:882; PMID:22112189; http://dx.doi.org/10.1186/1471-2458-11-882
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9; PMID:11172176; http://dx.doi.org/10.1056/NEJM200102083440602
   PubMed Web of Science ®Google Scholar
• Odusanya OO, Kuyinu YA, Kehinde OA, Shafi F, Francois N, Yarzabal JP, Dobbelaere K, Ruggeberg JU, Borys D, Schuerman L. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: booster dose and 2-dose catch-up regimens in the second year of life. Hum Vaccines Immunother 2014; 10:757-66; PMID:24356787; http://dx.doi.org/10.4161/hv.27276
   PubMed Web of Science ®Google Scholar
• Dicko A, Santara G, Mahamar A, Sidibe Y, Barry A, Dicko Y, Diallo A, Dolo A, Doumbo O, Shafi F, et al. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children. Hum Vaccines Immunother 2013; 9:382-8; PMID:23291945; http://dx.doi.org/10.4161/hv.22692
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214-22; PMID:23158882; http://dx.doi.org/10.1016/S0140-6736(12)61854-6
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014; 11:e1001657.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570-9; PMID:20384496; http://dx.doi.org/10.1086/652006
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Karppa T, Sadeharju K, Fanic A, Dieussaert I, Schuerman L. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. Pediatr Infect Dis J 2011; 30:e130-41; PMID:21540760; http://dx.doi.org/10.1097/INF.0b013e31821d1790
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez JA, Fresnadillo Martinez MJ. Dynamics of nasopharyngeal colonization by potential respiratory pathogens. J Antimicrobial Chemother 2002; 50 Suppl S2:59-73; PMID:12556435; http://dx.doi.org/10.1093/jac/dkf506
   PubMed Web of Science ®Google Scholar
• Odutola AA, Afolabi MO, Jafali J, Baldeh I, Owolabi OA, Owiafe P, Bah G, Jaiteh B, Mohammed NI, Donkor SA, et al. Haematological and biochemical reference values of Gambian infants. Trop Med Int Health 2014; 19:275-83; PMID:24393095; http://dx.doi.org/10.1111/tmi.12245
   PubMed Web of Science ®Google Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72; PMID:11238206
   PubMedGoogle Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356-60; PMID:16522777; http://dx.doi.org/10.1128/CVI.13.3.356-360.2006
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940; http://dx.doi.org/10.1128/CVI.00289-09
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415-22; PMID:9220157
   PubMedGoogle Scholar
• Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007; 25:2518-27; PMID:17034907; http://dx.doi.org/10.1016/j.vaccine.2006.09.029
   PubMed Web of Science ®Google Scholar
• Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, Khan MN, Bowsher RR. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Analysis 2000; 21:1249-73; PMID:10708409; http://dx.doi.org/10.1016/S0731-7085(99)00244-7
   PubMed Web of Science ®Google Scholar